The measure of the effectiveness of ZOSTAVAX was based on the number of people who developed shingles and post-herpetic pain during the study.
ZOSTAVAXi efektiivsuse mõõduks oli inimeste arv, kellel tekkis uuringu vältel vöötohatis ja herpesejärgne valu.